Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 3/20 | 0.59 |
| ▸ | CNR1 | P21554 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | PARG | Q86W56 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14606690 | 1.00 | GBA1 (0.59) | GBA1CNR2CNR1NPC1KMT2A | |
| SCHEMBL6799277 | 0.92 | GBA1 (0.69) | GBA1CNR2CNR1NPC1KMT2A | |
| SCHEMBL14606617 | 0.85 | ALDH1A1 (0.68) | GBA1KMT2AMEN1ALDH1A1CYP2C9 | |
| SCHEMBL14606888 | 0.85 | GBA1 (0.59) | GBA1KMT2AMEN1HTTALDH1A1 | |
| SCHEMBL14606669 | 0.85 | GBA1 (0.59) | GBA1CNR2CNR1KMT2AMEN1 | |
| SCHEMBL14606672 | 0.85 | ALDH1A1 (0.68) | GBA1KMT2AMEN1ALDH1A1CYP2C9 | |
| SCHEMBL14606725 | 0.85 | GBA1 (0.59) | GBA1CNR2CNR1KMT2AMEN1 | |
| SCHEMBL14606676 | 0.85 | GBA1 (0.59) | GBA1CNR2CNR1KMT2AMEN1 | |
| SCHEMBL14606884 | 0.85 | GBA1 (0.59) | GBA1KMT2AMEN1HTTALDH1A1 | |
| SCHEMBL14606609 | 0.84 | GBA1 (0.84) | GBA1KMT2AMEN1ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217001-B2 | Modification of feeding behavior | IMPERIAL INNOVATIONS LIMITED | 2012-07-10 | — | — | US | disclosed |
| US-7919329-B2 | Using proopiomelanocortin neuronal regulatory sequences to identify agents that affects caloric intake, energy expenditure, appetite or food intake; treating eating disorders and/or cachexia | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090209461-A1 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2009-08-20 | — | — | US | disclosed |
| EP-2050460-A1 | PYY and agonists thereof for modification of feeding behaviour | Imperial Innovations Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| US-7459432-B2 | Modification of feeding behavior | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2008-12-02 | — | — | US | disclosed |
| US-20080213803-A1 | ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR | OREGON HEALTH & SCIENCE UNIVERSITY | 2008-09-04 | — | — | US | disclosed |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| EP-1816127-A1 | TRIAZINE DERIVATIVES FOR USE AS SELECTIVE NPY (Y5) ANTAGONISTS | H. Lundbeck A/S (DK) | 2007-08-08 | — | — | EP | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
| US-6989379-B1 | Selective NPY (Y5) antagonists | H. LUNDBICK A/S (DK) | 2006-01-24 | — | — | US | disclosed |
| US-20050176630-A1 | adminsteration of Peptide YY or an agonist to a overweight subject, or having obesity related disorders, results in decreased food intake, caloric intake, appetite, and an alteration in energy metabolism | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-11 | — | — | US | disclosed |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| US-20050015820-A1 | Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-01-20 | — | — | US | disclosed |
| US-20040019050-A1 | Selective NPY (Y5) antagonists (triazines) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-01-29 | — | — | US | disclosed |
| US-6569856-B2 | Treatment of feeding disorders, obesity, bulimia nervosa, sexual/reproductive disorders, depression, epileptic seizure, cardiovascular disorders, sleep disturbances | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-20020103201-A1 | Selective NPY (Y5) antagonists (triazines) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-6340683-B1 | NEUROPEPTIDE Y ANTAGONISTS; TREATING EATING DISORDERS, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION, EPILEPTIC SEIZURE, HYPERTENSION, CEREBRAL HEMORRHAGE, CONGESTIVE HEART FAILURE, SLEEP DISTURBANCES | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019050-A1 | Selective NPY (Y5) antagonists (triazines) | NPY5R, NPY1R, NPY2R | GBA1 1028/4885CNR2 74/4885CNR1 110/4885 |
| US-20050176630-A1 | adminsteration of Peptide YY or an agonist to a overweight subject, or having obesity related disorders, results in decreased food intake, caloric intake, appetite, and an alteration in energy metabolism | NPY4R, NPY2R, NPY1R | GBA1 2999/4885CNR2 206/4885CNR1 271/4885 |
| US-20090209461-A1 | MODIFICATION OF FEEDING BEHAVIOR | NPY4R, NPY5R, NPY2R | GBA1 2807/4885CNR2 261/4885CNR1 250/4885 |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | GBA1 829/4885CNR2 44/4885CNR1 54/4885 |
| US-20020103201-A1 | Selective NPY (Y5) antagonists (triazines) | NPY5R, NPY1R, NPY2R | GBA1 1028/4885CNR2 74/4885CNR1 110/4885 |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | GBA1 829/4885CNR2 44/4885CNR1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.